13-Jul-2018 | Zion Market Research
Zion Market Research has published a new report titled “Macrolide Drugs Market by Drug Type (14-membered ring agents, 14-membered ring agents, 15-membered ring agents (Azalides), 16-membered ring agents, and Ketolides), By Distribution Channels (Hospital pharmacies, Clinics, Hospitals, Retail pharmacies, and Online pharmacies): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 – 2024”. According to the report, global macrolide drugs market was valued at approximately USD 6.14 billion in 2017 and is expected to generate revenue of around USD 7.66 billion by end of 2024, growing at a CAGR of around 3.2% between 2018 and 2024.
Macrolides are a class of antibacterial drugs that contain large macrocyclic lactone ring. One or more deoxy-sugars, usually desosamine and cladinose are attached to the macrocyclic lactone ring. The macrocyclic lactone ring generally is 14, 15 or 16 membered. Macrolides antibiotic is derived from Saccharopolyspora erythracea. Macrolides inhibit the protein synthesis in bacteria. The inhibition of protein synthesis is carried out by binding to the 50s ribosome. Macrolides are more effective against the gram-positive bacteria as well as the intracellular pathogens like Chlamydia, Mycoplasma, and Legionella. Macrolides primarily act as bacteriostatic agents opposite to several strains of Moxicella, Staphylococci Streptococci, Corynebacteria, Clostridia, Listeria, Neisseria meningitides, and Haemophilus sp.
Browse the full "Macrolide Drugs Market by Drug Type (14-membered ring agents, 14-membered ring agents, 15-membered ring agents (Azalides), 16-membered ring agents, and Ketolides), By Distribution Channels (Hospital pharmacies, Clinics, Hospitals, Retail pharmacies, and Online pharmacies): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 – 2024" report at https://www.zionmarketresearch.com/report/macrolide-drugs-market
Primary bacterial resistance to macrolides occurs due to the post-translational methylation of 23s bacterial rRNA. Because of mutation, the bacterial resistance is either plasmid-mediated or chromosomal. This results in the cross-resistance of macrolides, streptogramins, and lincosamides. Other two rarely seen acquired resistances are the production of drug-inactivating enzymes, as well as the production of active ATP-dependent efflux proteins which transport the drug outside of the cell.
Macrolide drugs market is expected to have a moderate growth during the forecast period attributing to the increasing prevalence of infectious diseases, in turn increasing the demand for drugs against the infections. Furthermore, a rising elderly population, the alarming rate of increasing number of multi-strain resistant bacterial strains as well as better benefits over the conventional antibiotics are driving factors for the macrolide drugs market. Macrolide drug is good for oral absorption, it is easy for absorption in tissues and also has an easier dosage of once or twice a day. Macrolide drug has very low incidences of side-effects. A study stated that macrolide may increase the risk of a sudden cardiac arrest, ventricular tachyarrythmias, and cardiovascular deaths, also GI disturbances and inhibition of hepatic metabolism may hinder the growth of macrolide drugs market.
Based on the type, macrolide drugs market has been segmented into 14-membered ring agents, 14-membered ring agents, 15-membered ring agents (Azalides), 16-membered ring agents, and Ketolides. Based on the sales channel, macrolide drugs market has been segmented into hospitals, clinics, hospital pharmacies, retail pharmacies, and online pharmacies. Based on region, the macrolide drugs market is further segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America is expected to remain the principal region over the forecast period. Rising healthcare understanding and awareness about the drugs against the infections is expected to boost the market in this region. Europe was the second largest market followed by Asia Pacific. Asia Pacific is expected to show the fastest growth rate during the forecast period while Latin America market is projected to grow at a moderate rate during the forecast period. The Middle East and Africa are also expected to experience noticeable growth in the years to come with increasing awareness.
Some of the key players in macrolide drugs market include Abbott Laboratories, Akorn, Inc., Eli Lilly & Co., Fresenius Kabi USA, Gland Pharma Limited, Neo Química, Macrolide Pharmaceuticals, Mylan N.V., Pfizer, Inc., Sanofi, Merck & Co., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and WOCKHARDT, among others.
This report segments the global macrolide drugs market as follows:
Global Macrolide Drugs Market: By Type
Global Macrolide Drugs Market: By Sales Channel
Global Macrolide Drugs Market: By Region
Browse New Press Release: https://www.zionmarketresearch.com/news/macrolide-drugs-industry
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651